Antibiotics in childhood pneumonia: how long is long enough?
Pneumonia volume 8, Article number: 6 (2016)
Improved access to healthcare, vaccines and treatment with antibiotics has reduced global mortality from childhood community-acquired pneumonia. However, as respiratory viruses are responsible for most episodes of pneumonia, important questions remain over who should receive these agents and the length of each treatment course. Worldwide concerns with increasing antibiotic resistance in respiratory pathogens and appeals for more prudent antibiotic prescribing provide further urgency to these clinical questions. Unfortunately, guidelines for treatment duration in particular are based upon limited (and often weak) evidence, resulting in national and international guidelines recommending treatment courses for uncomplicated pneumonia ranging from 3 to 10 days. The advantages of short-course therapy include a lower risk of developing antibiotic resistance, improved adherence, fewer adverse drug effects, and reduced costs. The risks include treatment failure, leading to increased short- or long-term morbidity, or even death. The initial challenge is how to distinguish between bacterial and non-bacterial causes of pneumonia and then to undertake adequately powered randomised-controlled trials of varying antibiotic treatment durations in children who are most likely to have bacterial pneumonia. Meanwhile, healthcare workers should recognise the limitations of current pneumonia treatment guidelines and remember that antibiotic course duration is also determined by the child’s response to therapy.
Community-acquired pneumonia is the leading global cause of childhood morbidity and mortality. Annually, there are an estimated 120–160 million clinical pneumonia episodes worldwide, causing 14 million hospitalisations and almost one million deaths in children aged <5 years [1, 2]. Although respiratory viruses are the most common pathogens associated with childhood pneumonia, most deaths are attributed to Streptococcus pneumoniae and Haemophilus influenzae type b . Consequently, antibiotics have reduced pneumonia-related morbidity and mortality. Nevertheless, several knowledge gaps exist with prescribing antibiotics for pneumonia, including the optimal length of treatment required. These limitations are evident in both national and international guidelines, which have had to rely upon expert opinion and weak levels of evidence from a small number of clinical trials with substantial methodological limitations [4–7]. A good example of these difficulties is the range of recommendations provided on treatment duration for uncomplicated childhood pneumonia [5, 6]. This raises several questions for healthcare workers when determining how long they should be giving antibiotics to a child with pneumonia.
What factors influence decisions on antibiotic duration?
Several factors are considered when both choosing an antibiotic to treat a suspected case of bacterial pneumonia and determining how long it should be given. These include: (i) clinical presentation and severity; (ii) assumed bacterial aetiology based upon the child’s age, vaccination status, underlying co-morbidities and the local pathogen antibiotic susceptibility profiles; and (iii) cost, availability, tolerability, and ease of administration (e.g. frequency and palatability) of the chosen agent that may influence treatment adherence.
In clinical practice, the optimal duration of antibiotic treatment depends upon whether the pneumonia is straightforward or complicated (e.g. empyema or systemic infection involving other organs); if underlying medical disorders are present (e.g. malnutrition, human immunodeficiency virus infection, or chronic cardiopulmonary disease); the nature of the causative pathogen, adequacy of source control, and the patient’s response to treatment.
In uncomplicated pneumonia the advantages of a short-treatment course include a lower risk of developing antibiotic resistance, improved adherence, fewer adverse effects, and decreased costs [6, 8]. The main danger though of shortened therapy in young children is treatment failure from delayed or incomplete eradication of the infecting pathogen(s), risking additional morbidity and injury to the developing lungs and possibly a greater chance of impaired lung function, chronic obstructive pulmonary disease and bronchiectasis later in life .
It is really bacterial pneumonia?
Most studies on antibiotic duration were undertaken in low- and low-to-middle-income countries where the burden of pneumonia is greatest. Unfortunately, the diagnosis of bacterial pneumonia in these settings is also the most uncertain as it relies upon healthcare workers following clinical algorithms without adequate laboratory and radiographic support. Furthermore, no diagnostic gold standard for pneumonia exists, and there are major difficulties differentiating between viral and bacterial pneumonia clinically and radiographically, let alone obtaining an accurate microbiological cause .
What are the current recommendations and what are their limitations?
As most childhood pneumonia deaths occur out of hospital in the low-resource settings of sub-Saharan Africa and Southern Asia, the diagnostic algorithms used by the World Health Organization (WHO) are designed to reduce mortality, sacrificing specificity for sensitivity . Otherwise healthy children with suspected clinical pneumonia are managed as outpatients and receive either 3 days of high-dose oral amoxicillin (80–90 mg/kg/day) if tachypnoeic alone, or 5 days if subcostal recession is also present . Those with severe clinical pneumonia accompanied by danger signs (e.g. dehydration, seizures, or altered consciousness) receive parenteral penicillin (or ampicillin) and gentamicin as first-line agents for at least 5 days. These recommendations are based upon several large randomised controlled trials (RCTs) of oral vs. parenteral antibiotics and 3 vs. 5 days of oral antibiotic treatment in children from developing countries [7, 11]. A recent systematic review published in the journal  found three RCTs from developing countries comparing short (3 days) vs. standard (5 days) oral antibiotic treatments in children with non-severe (tachypnoea alone) pneumonia. These studies were conducted in either India or Pakistan and each involved >2000 children aged 2–59 months [12–14]. Each reported that 3 days was either equivalent  or not statistically different [13, 14] to 5 days treatment. However, the validity of these three studies is questionable. The follow-up was limited to only 14 days and although failure rates ranged from 9.5 % to 21 %, just a single death occurred in a 3-month old infant amongst the 6197 trial subjects, a much lower case fatality than expected for pneumonia in these settings [2, 3]. Almost half the subjects were infants, as many as 22 % had wheeze, and pneumonia was diagnosed following the WHO clinical algorithm . Only one study included chest radiographs , where just one in seven children with clinical pneumonia had abnormal radiographic findings. Consequently, these studies of treating non-severe pneumonia in developing countries are limited by inherent biases towards equivalence of varying treatment durations, since many (if not most) participating subjects were unlikely to benefit from antibiotics as they had bronchiolitis, viral pneumonia, or virus-associated wheeze. Indeed, a recent double-blind RCT in 900 children aged 2–59 months from Pakistan with WHO-diagnosed non-severe pneumonia found equivalent clinical outcomes in those receiving either 3 days of oral amoxicillin or placebo with cumulative treatment failure rates by day 5 of 13.5 % and 17.6 %, respectively, while once again no deaths were reported .
In contrast to developing countries, criteria for diagnosing childhood pneumonia in developed nations often require chest radiographic confirmation, especially for hospitalised cases . Nevertheless, little information is available guiding treatment duration [6, 7], although a recent small, single-centre, three-arm RCT from Israel of 140 non-hospitalised children aged <5 years with likely bacterial pneumonia (based on clinical criteria, chest radiographic consolidation, and raised white blood cell counts) found that the 40 % failure rate of a 3 day course of amoxicillin was unacceptably high, while no failures were reported in those receiving either a 5 or 10 days course of the antibiotic . These data help support current national guidelines from developed countries recommending at least 5 days of antibiotics for children suspected of bacterial pneumonia [5, 6].
So, what is required?
The guidelines for the treatment duration of pneumonia are based upon limited and often weak evidence [4–7]. The situation is not helped by the important knowledge gaps that still remain regarding how to best identify children with pneumonia, including how to reliably differentiate between bacterial and non-bacterial causes . Healthcare workers in resource poor settings in particular need access to validated, simple, and inexpensive point-of-care diagnostic tests. Unfortunately, none are likely to be available soon. While new technologies such as gene expression signatures show considerable promise for identifying aetiological pathogens in pneumonia, these and other molecular-based platforms are unlikely to be made available in the foreseeable future to low- and middle-income countries where the burden of pneumonia is greatest. Meanwhile, although there is mounting global concern over rising rates of antibiotic resistance resulting in increased calls for shorter treatment courses, it is important to remember that an ineffective short antibiotic treatment course for pneumonia is still the worst strategy when either it is not needed (e.g. for viral respiratory infections) or when it results in treatment failure, risking death, increased morbidity and/or long-term sequelae [8–10].
Clearly, more robust evidence for antibiotic treatment duration for pneumonia is needed. A good start would be to undertake additional RCTs in sub-Saharan Africa and Asia (where feasible sample sizes are possible), recruiting subjects with a greater probability of bacterial infection (based on clinical severity or radiographic criteria). Meanwhile, healthcare workers should recognise the limitations of current “one size fits all” pneumonia treatment guidelines and remember that the duration of antibiotic therapy is also determined by individual host and pathogen factors and how the child responds to treatment.
Madhi SA, De Wals P, Grijalva CG, Grimwood K, Grossman R, Ishiwada N, et al. The burden of childhood pneumonia in the developed world: a review of the literature. Pediatr Infect Dis J. 2013;32:e119–27.
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71.
Rudan I, O’Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health. 2013;3:010401.
World Health Organization. Revised WHO classification and treatment of childhood pneumonia at health facilities. Evidence summaries. Geneva, Switzerland: WHO Press, World Health Organization; 2014.
Nascimento-Carvelho CM, Madhi SA, O’Brien KL. Review of guidelines for evidence-based management for childhood community-acquired pneumonia in under-5 years from developed and developing countries. Pediatr Infect Dis J. 2013;32:1281–2.
Kerrison C, Riordan FAI. How long should we treat this infection for? Arch Dis Child Educ Pract. 2013;98:136–40.
Ben-Shimol S, Levy-Litan V, Falup-Pecurariu O, Greenberg D. Evidence for short duration of antibiotic treatment for non-severe community acquired pneumonia (CAP) in children – are we there yet? A systematic review of randomised controlled trials. Pneumonia. 2014;4:16–23.
Valiquette L, Laupland KB. Get shorty! Can J Infect Dis Med Microbiol. 2015;26:174–7.
Grimwood K, Chang AB. Long-term effects of pneumonia in young children. Pneumonia. 2015;6:101–14.
Chang AB, Ooi MH, Perera D, Grimwood K. Improving the diagnosis, management, and outcomes of children with pneumonia: where are the gaps? Front Pediatr. 2013;1:29.
Lassi ZS, Das JK, Haider SW, Salam RA, Qazi SA, Bhutta ZA. Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age. Arch Dis Child. 2014;99:687–93.
Pakistan Multicentre Amoxicillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet. 2002;360:835–41.
ISCAP Study Group. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. Brit Med J. 2004;328(7443):791.
Awasthi SA, Agarwal G, Singh JV, Kabra SK, Pillai RM, Singhi S, et al. Effectiveness of 3-day amoxycillin vs 5-day co-trimoxazole in the treatment of non-severe pneumonia in children 2–59 months of age: a multi-centric open labeled trial. J Trop Pediatr. 2008;54:382–9.
Hazir T, Nisar YB, Abbasi S, Ashraf YP, Khurshid J, Tariq P, et al. Comparison of oral amoxicillin with placebo for the treatment of World Health Organization-defined nonsevere pneumonia in children aged 2–59 months: a multicentre, double-blind, randomized, placebo-controlled trial in Pakistan. Clin Infect Dis. 2011;52:293–300.
Greenberg D, Givon-Lavi N, Sadaka Y, Ben-Shimol S, Bar-Ziv J, Dagan R. Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children. A double-blind, randomized, placebo-controlled trial. Pediatr Infect Dis J. 2014;33:136–42.
ABC is funded by an Australian National Health and Medical Research Council (NHMRC) practitioner fellowship (1058213). KG and AC currently hold a NHMRC Centre of Research Excellence grant (1040830) on lung health in Indigenous children. AMN is funded by a University Malaya Research Grant (UMRG) (RP026-14HTM), University Malaya, Kuala Lumpur, Malaysia. All authors are investigators on an NHMRC project grant (1098443) supporting a randomised controlled trial of antibiotic treatment for community acquired pneumonia in Indigenous children and in children from a developing country.
In the last 5 years, KG has been a member of advisory boards on pneumonia, otitis media, and pneumococcal conjugate vaccines for GlaxoSmithKline (GSK) Biologicals, Rixensart, Belgium. SMF has received investigator-driven grants from GSK and Merck Sharp & Dohme, United States of America. AMN has received honoraria from GSK for giving lectures on behalf of the company. ABC has received an investigator-driven grant from GSK evaluating the impact of a vaccine on the lower airways of children. MHO had no competing interests to declare.
KG conceived and wrote the first draft of the manuscript. All authors contributed to revising the manuscript and approved the final version.